22nd Century Group Announces Exercise of Existing Warrants and Fundraising

Business by 2FIRSTS.ai

Dec.05.2023

22nd Century Group Announces Exercise of Existing Warrants and Fundraising

BioTech company 22nd Century Group, Inc. announced the exercise of existing options by shareholders, generating approximately $3.2 million in revenue.

According to a report published by Menafn on December 4th, the biotechnology company 22nd Century Group, Inc. (NASDAQ: XXII), based in Buffalo, New York, announced that some holders plan to exercise their existing stock options as part of the previously disclosed incentive stock option program.

During this exercise period, several existing stock option holders of the company purchased a total of 14,767,386 common shares at a reduced exercise price of $0.215 per share.

Currently, the company has received a total gross income of approximately 3.2 million dollars.

The newly appointed Chairman and CEO, Larry Firestone, has announced that this funding will serve as crucial operational capital to support the company's tobacco business and drive its restructuring efforts to enhance performance in the tobacco industry and reduce operational costs.

References:

[1] 22Nd Century Secures $3.2 Million To Date In Warrant Exchange Transaction

Also Read:

[1] 22nd Century Group Announces Exercise of Existing Warrants and Fundraising

[2] 22nd Century Group Inc's Stock Drops 12.26%, but Shows Recent Recovery

#North America #United States #Traditional tobacco #Personnel announcement #Charity

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

ceshi1111

Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st

Oct.21

JT Q3 2025: Revenue +18%, Profit +30%; RRP Volume +40%; Guidance Up

Japan Tobacco (JT) delivered a strong Q3 2025. Revenue rose 18.3% year over year to ¥947.2 billion, with adjusted operating profit up 27.8% to ¥279.0 billion (+20.8% at constant currency) and net profit up 29.7% to ¥176.7 billion. Growth was led by reduced-risk products (RRP): total RRP volume climbed 40%, with heated tobacco (HTS) up 53%. In Japan, the launches of Ploom AURA and EVO pods pushed HTS category share to 15.5%, while the Ploom user base has nearly doubled versus two years ago.

Oct.30 by 2FIRSTS.ai

Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways

2Firsts analyzes vaping regulations across the Baltic states. Following Latvia’s flavor ban, tax revenues fell and the black market expanded, while similar measures in Estonia and Lithuania have also failed to deliver results. The region’s anti-vaping policies are now triggering market imbalance and policy reassessment.

Oct.13

Smoore and EVE Energy Sign Procurement Framework Agreement Covering 2026–2028 Cell Supply

Smoore and EVE Energy have signed a procurement framework agreement for 2026–2028, under which Smoore Group will continue purchasing battery cells and related products. The agreement sets no specific transaction amount; actual figures will be determined by future orders, reflecting both parties’ intention to secure and extend their supply chain cooperation over the next three years.